Evaluation of Flowmetry Indicators in Patients with a Wet AMD Form during Antiangiogenic Therapy

Purpose: to assess the effect of aflibercept (Eylea; “Regeneron”, USA) intravitreal injections on ocular blood flow and intraocular pressure parameters in patients with neovascular form of age-related macular degeneration (wet AMD). Currently, neovascular agerelated macular degeneration (wet AMD) is one of the leading causes of irreversible vision loss and blindness among populations over the age of 50.

Material and methods. The study included 35 patients (35 eyes), 10 men and 25 women. Mean patients’ age was 72 ± 6 years. The inclusion criteria were the established diagnosis of a neovascular form of age-related macular degeneration and the level of ophthalmotonus not more than the accepted upper limit of the average norm — IOP 21 mm hg prior to drug administration of the drug. All patients underwent flowmetry with ocular blood flow (OBF) volume determination and intraocular pressure (IOP) measurement. The patients received a singular intravitreal aflibercet injection (2 ml). OBF and IOP were measured at baseline before the injection and the on day 4 and 1 month after the injection.

Results. There was no statisticaly significant difference between the IOP level before and after the injection. We revealed a tendency towards OBF decrease in 1 month after the injection, but overall values and the decrease both 4 days and 1 month after the intravitreal injection did not prove to be statistically significant. The absence of statistically significant changes of intraocular pressure level and volumetric ocular blood flow additionally confirms information about the safety of intravitreal administration of aflibercept to patients with a wet form of age-related macular degeneration.

1. Garcia‑Layana A., Figueroa M.S., Araiz J. Treatment of Exudative Age‑related Macular Degeneration: Focus on Aflibercept. Drugs Aging. 2015;32:797–807. DOI: 10.1007/s40266‑015‑0300‑y

2. WHO/World Health Organization. Age Related Macular Degeneration: Priority eye diseases. [Last accessed on 2011 Feb 6]. Available from: http://www.who.int/blindness/causes/priority/en/index8.html

3. Heier J.S., Brown D.M., Chong V., et al. Intravitreal aflibercept (VEGF trap‑eye) in wet age‑related macular degeneration. Ophthalmology. 2012;119:2537–2548. DOI: 10.1016/j.ophtha.2012.09.006

4. Budzinskaya M.V. Century. Age‑related macular degeneration. Annals of Ophthalmology = Vestnik oftal’mologii. 2014;130(6):56–61 (In Russ.)

5. Neroev V.V. Russian observational epidemiological non‑interventional study of patients with a wet form of age‑related macular degeneration. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2011;4(2):4–9 (In Russ.)

6. Holz F.G., Tadayoni R., Beatty S. Multi‑country real‑life experience of antivascular endothelial growth factor therapy of wet age‑related macular degeneration. British Journal of Ophthalmology. 2015;99:220–226. DOI: 10.1136/bjophthal‑mol‑2014‑305327

7. Folkman J. What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute. 1990;82(1):4–6.

8. Garcia‑Layana A., Figueroa M.S., Araiz J. Treatment of Exudative Age‑related Macular Degeneration: Focus on Aflibercept. Drugs Aging. 2015;32:797–807. DOI: 10.1007/s40266‑015‑0300‑y

9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine reviews. 2004;25(4):581–611. DOI: 10.1210/er.2003‑0027

10. Heier J.S., Brown D.M., Chong V., et al. Intravitreal aflibercept (VEGF trap‑eye) in wet age‑related macular degeneration. Ophthalmology. 2012;119:2537–2548. DOI: 10.1016/j.ophtha.2012.09.006

11. Holz F.G., Tadayoni R., Beatty S. Multi‑country real‑life experience of antivascular endothelial growth factor therapy of wet age‑related macular degeneration. British Journal of Ophthalmology. 2015;99:220–226. DOI: 10.1136/bjophthal‑mol‑2014‑305327

12. Gunther J.B., Altaweel M.M. Bevacizumab (Avastin) for the Treatment of Ocular Disease. Survey of Ophthalmology. 2009;54(3):372–400. DOI: 10.1016/j.survoph‑thal.2009.02.004

13. Folkman J. What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute. 1990;82(1):4–6.

14. Ng E.W., Shima D.T., Calias P. Pegaptanib, a targeted anti‑VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5(2):123–132. DOI: 10.1038/nrd1955

15. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine reviews. 2004;25(4):581–611. DOI: 10.1210/er.2003‑0027

16. André T., Chibaudel B. Aflibercept (Zaltrap(®) approved in metastatic colorectal cancer. Bulletin du cancer. 2013;100(10):1023–1025. DOI: 10.1684/bdc.2013.1807

17. Gunther J.B., Altaweel M.M. Bevacizumab (Avastin) for the Treatment of Ocular Disease. Survey of Ophthalmology. 2009;54(3):372–400. DOI: 10.1016/j.survoph‑thal.2009.02.004

18. Singh S.R., Dogra A., Steward M., Das T., Chhablani J. Intravitreal ziv‑aflibercept: Clinical Effects and Econmic Impact. Asia Pac J Ophthalmol (Phila) 2017;6:561–568. DOI: 10.22608/APO.2017263

19. Ng E.W., Shima D.T., Calias P. Pegaptanib, a targeted anti‑VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5(2):123–132. DOI: 10.1038/nrd1955

20. Schmidt‑Erfurth U., Kaiser P.K., Korobelnik J.F. Intravitreal aflibercept injection for neovascular age‑related macular degeneration: ninety‑six week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201. DOI: 10.1016/j.ophtha.2013.08.011

21. Ohnaka M., Nagai Y., Sho K., Miki K., Kimura M., Chihara T. A modified treatand‑extend regimen of aflibercept for treatment‑naive patients with neovascular age‑related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017 Apr;255(4):657–664. DOI: 10.1007/s00417‑016‑3507‑7

22. André T., Chibaudel B. Aflibercept (Zaltrap(®) approved in metastatic colorectal cancer. Bulletin du cancer. 2013;100(10):1023–1025. DOI: 10.1684/bdc.2013.1807

23. Lotery A., Griner R., Ferreira A., Milnes F., Dugel P. Real‑world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye (Lond). 2017 Dec;31(12):1697–1706. DOI: 10.1038/eye.2017.143

24. Singh S.R., Dogra A., Steward M., Das T., Chhablani J. Intravitreal ziv‑aflibercept: Clinical Effects and Econmic Impact. Asia Pac J Ophthalmol (Phila) 2017;6:561–568. DOI: 10.22608/APO.2017263

25. Lee J.W., Park H., Choi J.H. Short‑term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthalmol. 2016;16:69. DOI: 10.1186/s12886‑016‑0255‑8

26. Schmidt‑Erfurth U., Kaiser P.K., Korobelnik J.F. Intravitreal aflibercept injection for neovascular age‑related macular degeneration: ninety‑six week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201. DOI: 10.1016/j.ophtha.2013.08.011

27. Lee A.Y., Lee C.S., Egan C.A., Bailey C., Johnston R.L., Natha S., Hamilton R., Khan R., Al‑Husainy S., Brand C., Akerele T., Mckibbin M., Downey L., Tufail A. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. Br J Ophthalmol. 2017 Dec;101(12):1683–1688. DOI: 10.1136/bjophthalmol‑2016‑309818

28. Ohnaka M., Nagai Y., Sho K., Miki K., Kimura M., Chihara T. A modified treatand‑extend regimen of aflibercept for treatment‑naive patients with neovascular age‑related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017 Apr;255(4):657–664. DOI: 10.1007/s00417‑016‑3507‑7

29. Neroev V.V., Kiseleva T.N., Okhotsimskaya T.D., Fadeeva V.A., Ramazanova K.A. The effect of antiangiogenic therapy on ocular blood flow and microcirculation in diabetic macular edema. Annals of Ophthalmology = Vestnik oftal’mologii. 2018;134(4):3–10 (In Russ.). DOI: 10.17116/oftalma20181340413

30. Lotery A., Griner R., Ferreira A., Milnes F., Dugel P. Real‑world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye (Lond). 2017 Dec;31(12):1697–1706. DOI: 10.1038/eye.2017.143

31. Rechtman E., Stalmans I., Glovinsky J., Breusegem C., Moisseiev J., Van Calster J., Harris A. The effect of intravitreal bevacizumab9 Avastin) on ocular pulse amplitudein neovascular age‑related macular degeneration. Clin.Ophtalmol. 2011;5:37–44.

32. Lee J.W., Park H., Choi J.H. Short‑term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthalmol. 2016;16:69. DOI: 10.1186/s12886‑016‑0255‑8

33. Bonnin P., Pournaras J.A., Lazrak Z. Ultrasound assessment of short‑term ocular vascular effects of intravitreal injection of bevacizumab (Avastin) in neovascular age‑related macular degeneration. Acta Ophthalmol. 2010;88(6):641–645. DOI: 10.1111/j.1755‑3768.2009.01526.x

34. Lee A.Y., Lee C.S., Egan C.A., Bailey C., Johnston R.L., Natha S., Hamilton R., Khan R., Al‑Husainy S., Brand C., Akerele T., Mckibbin M., Downey L., Tufail A. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. Br J Ophthalmol. 2017 Dec;101(12):1683–1688. DOI: 10.1136/bjophthalmol‑2016‑309818

35. Bonnin P., Pournaras J.A., Makowiecka K., et al. Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age‑related macular degeneration. Acta Ophthalmol. 2014;92(5):e382–e387. DOI: 10.1111/aos.12356

36. Neroev V.V., Kiseleva T.N., Okhotsimskaya T.D., Fadeeva V.A., Ramazanova K.A. The effect of antiangiogenic therapy on ocular blood flow and microcirculation in diabetic macular edema. Annals of Ophthalmology = Vestnik oftal’mologii. 2018;134(4):3–10 (In Russ.). DOI: 10.17116/oftalma20181340413

37. Shahin M., Gad M.A., Hamza W. Impact of intravitreal triamcinolone acetonide versus intravitreal bevacizumab on retrobulbar hemodynamic in patients with diabetic macular edema. Cutan Ocul Toxicol. 2014;33:49–53. DOI: 10.3109/15569527.2013.796478

38. Rechtman E., Stalmans I., Glovinsky J., Breusegem C., Moisseiev J., Van Calster J., Harris A. The effect of intravitreal bevacizumab9 Avastin) on ocular pulse amplitudein neovascular age‑related macular degeneration. Clin.Ophtalmol. 2011;5:37–44.

39. Sacu S., Pemp B., Weigert G. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti‑VEGF treatment in eyes with branch retinal vein occlusion. Investigative. Ophthalmology and Visual Science. 2011;52(6):3046–3050. DOI: 10.1167/iovs.10‑5842

40. Bonnin P., Pournaras J.A., Lazrak Z. Ultrasound assessment of short‑term ocular vascular effects of intravitreal injection of bevacizumab (Avastin) in neovascular age‑related macular degeneration. Acta Ophthalmol. 2010;88(6):641–645. DOI: 10.1111/j.1755‑3768.2009.01526.x

41. Rechtman E., Stalmans I., Glovinsky J. The effect of intravitreal bevacizumab (Avastin) on ocular pulse amplitude in neovascular age‑related macular degeneration. Clin Ophthalmol. 2011;5:37–44. DOI: 10.2147/OPTH.S15810

42. Bonnin P., Pournaras J.A., Makowiecka K., et al. Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age‑related macular degeneration. Acta Ophthalmol. 2014;92(5):e382–e387. DOI: 10.1111/aos.12356

43. Shahin M., Gad M.A., Hamza W. Impact of intravitreal triamcinolone acetonide versus intravitreal bevacizumab on retrobulbar hemodynamic in patients with diabetic macular edema. Cutan Ocul Toxicol. 2014;33:49–53. DOI: 10.3109/15569527.2013.796478

44. Sacu S., Pemp B., Weigert G. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti‑VEGF treatment in eyes with branch retinal vein occlusion. Investigative. Ophthalmology and Visual Science. 2011;52(6):3046–3050. DOI: 10.1167/iovs.10‑5842

45. Rechtman E., Stalmans I., Glovinsky J. The effect of intravitreal bevacizumab (Avastin) on ocular pulse amplitude in neovascular age‑related macular degeneration. Clin Ophthalmol. 2011;5:37–44. DOI: 10.2147/OPTH.S15810